The court granted Bluebird's request for summary judgment, effectively concluding the patent challenge brought forth by San Rocco Therapeutics.

Judge Richard G. Andrews determined that Bluebird's therapies do not infringe upon the patented gene-therapy technology held by San Rocco.

This ruling came after San Rocco had previously narrowed its patent claims to a specific DNA sequence that Bluebird's therapies do not utilize, which was pivotal in the court's decision of noninfringement.

Bluebird Bio Inc. achieved a significant legal victory in a patent dispute regarding its gene therapies, Zynteglo and Lyfgenia, as a Delaware federal judge ruled in their favor on May 16, 2025.